Blank Rome partner Rachael G. Pontikes will serve as a panelist at the Food and Drug Law Institute’s (“FDLI”) 2026 Annual Conference, being held May 6 through 7, 2026, in Washington, D.C. Blank Rome is pleased to be a Gold Sponsor of the conference.

About the Conference

The FDLI Annual Conference provides an opportunity to delve into the complex legal, regulatory, compliance, and policy issues currently impacting the U.S. Food and Drug Administration (“FDA”)-regulated industry. Speakers include professionals from the federal government, industry, the private bar, patient and consumer advocacy groups, consulting organizations, and academia.

Rachael, who is a member of the conference planning committee, will speak on the “Compounding Conundrums: SAFE Act, State Bills, and FDA Scrutiny” panel, taking place on Thursday, May 7, from 1:45 to 2:45 p.m.

About the Session

Panelists will discuss recent compounding updates, including federal developments from the SAFE Act to FDA updates on the green list and Category II peptide restrictions; advertising scrutiny and high-profile lawsuits tied to compounded products, including GLP-1s; and state legislative activity affecting Active Pharmaceutical Ingredients (“API”) sourcing, substance limits, labeling, and pharmacy operations.

Panelists:

  • Moderator: Julie A. Dohm, Partner, Covington & Burling LLP
  • Ilisa Bernstein, Principal & Co-Founder, Compounding Strategy Advisors, LLC
  • Matthew Lash, Acting Director, Office of Compounding Quality and Compliance, Office of Compliance, CDER, FDA
  • Rachael G. Pontikes, Partner, Blank Rome LLP
  • Scott Brunner, Chief Executive Officer, Alliance for Pharmacy Compounding

For more information, please visit the conference webpage.